Dr Vinai Gondi  speaks to ecancer about the final results of the phase 3 METIS trial.

This trial evaluated tumour treating fields (TTFields) as an adjunct to stereotactic radiosurgery (SRS) in patients with 1–10 newly diagnosed brain metastases from non-small cell lung cancer (NSCLC).

Dr Gondi highlights the results saying that adding TTFields after SRS significantly delayed intracranial progression compared to SRS alone, with lower progression rates observed through 24 months. The benefit was more pronounced in patients also receiving immune checkpoint inhibitors.

He says that reported side effects were mostly mild to moderate scalp reactions and these findings suggest that TTFields therapy following SRS may be a safe and effective strategy to extend intracranial disease control in patients with NSCLC brain metastases while maintaining cognitive function and quality of life.